Insigneo Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$338K Sell
437
-8
-2% -$6.13K 0.02% 467
2025
Q4
$343K Buy
445
+13
+3% +$8.83K 0.02% 470
2025
Q3
$243K Buy
432
+45
+12% +$25.4K 0.02% 576
2025
Q2
$203K Sell
387
-24
-6% -$13.4K 0.02% 567
2025
Q1
$261K Sell
411
-9
-2% -$6.19K 0.03% 448
2024
Q4
$299K Sell
420
-416
-50% -$349K 0.03% 419
2024
Q3
$878K Sell
836
-223
-21% -$248K 0.09% 195
2024
Q2
$1.13M Buy
1,059
+107
+11% +$104K 0.13% 155
2024
Q1
$916K Buy
952
+250
+36% +$238K 0.11% 175
2023
Q4
$617K Buy
702
+305
+77% +$251K 0.09% 206
2023
Q3
$327K Buy
397
+42
+12% +$33K 0.07% 269
2023
Q2
$255K Buy
+355
New +$274K 0.05% 314

Other funds holding REGN

Insigneo Advisory Services's REGN Position: Q1 2026 in Review

Insigneo Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 1.8% in Q1 2026, selling an estimated $6.13K and leaving 437 shares worth $338K. The position accounts for 0.02% of the portfolio, ranked #467.

Insigneo Advisory Services first reported a position in REGN in Q2 2023 and has held it in 12 quarters since. The position peaked at $1.13M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Insigneo Advisory Services held 437 shares of Regeneron Pharmaceuticals worth $338K as of Q1 2026.
  • Insigneo Advisory Services sold 8 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.13K.
  • Regeneron Pharmaceuticals made up 0.02% of Insigneo Advisory Services's portfolio in Q1 2026, its #467 holding.
  • Insigneo Advisory Services first reported a position in Regeneron Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Insigneo Advisory Services's Regeneron Pharmaceuticals position peaked at $1.13M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Insigneo Advisory Services's 13F filing for Q1 2026, filed 12 May 2026.